Navigation Links
Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
Date:1/15/2009

    ANTONY, France, January 15 /PRNewswire-FirstCall/ --

       EUR millions           2007          07/06         2008        08/07
                           EUR     % sales % change   EUR    % sales % change
                        millions                    millions

    Southern Europe (1)   32.0       75       14      36.4     73       14
    Other EU Countries     9.7       22       17      11.3     23       17
    (2)
    Other markets          1.4        3       10      2.0       4       45
    SLIT                  34.6       80       21      40.4     81       17
    SCIT                   7.1       17       4       7.5      15       6
    Other products         1.4        3      (25)     1.8       4       32
    Total Q4 sales        43.1       100      15      49.7     100      15
    Southern Europe (1)   109.2      74       17     124.9     73       14
    Other EU countries    32.5       22       16      38.5     23       18
    (2)
    Other markets          5.4        4       11      7.5       4       38
    SLIT                  116.5      79       21     137.9     81       18
    SCIT                  24.9       17       3       26.3     15       6
    Other products         5.7        4      (7)      6.7       4       16
    Cumulative 12-month   147.1      100      16     170.9     100      16
    sales

    (1) Portugal, Spain, France, Italy, Greece; (2) Switzerland included
    Sales growth and financial position, 2009 outlook

4th quarter sales continued to register strong growth in all markets (up 15%, after 15% in 2007). The performance of non-EU markets in particular was remarkable during the quarter, as throughout the whole year. The sub-lingual route remained the main driver of this growth with an 18% increase over the financial year.

Overall, 2008 sales totalled EUR 170.9 million, an increase of 16%, in line with the strong growth consistently achieved since 2003 (average 15% annual growth).

Full-year results will be markedly improved compared to 2007, which will enable the Group to finance its development plans while maintaining a positive free cash flow for the fourth consecutive year.

As regards 2009, the Group remains prudent and currently provides guidance of sales growth between 8 and 10%. 2009 will also feature a number of significant clinical test results as part of the Oralair programme.

Significant 4th quarter transactions and events

Oralair(R) Grasses quarterly sales in Germany were in line with expectations. The marketing authorization for the use Oralair(R) Grasses on children, which should be delivered very soon by the German agency, will set the European mutual recognition procedure of the product in motion.

On October 27, 2008, Stallergenes obtained authorization (IND) from the FDA for the use of Oralair(R) Grasses in clinical trials in adults. This study is proceeding satisfactorily.

In order to exert better control over its operations in Switzerland and Austria, Stallergenes has launched a procedure aiming at having subsidiaries distribute its products in these two countries from the start of 2009. At the end of this procedure, Stallergenes will have a subsidiary in Austria and its current distributor in Switzerland, TRIMEDAL, will join the Stallergenes Group.

Corporate governance

At today's meeting, the Board of Directors took note of the AFEP/MEDEF recommendations of October 6, 2008 on the remuneration of directors of listed companies. The Board considers that these recommendations are consistent with the Company's corporate governance policy and gave the Remuneration Committee the responsibility to carry out a detailed review of the rules governing their implementation within the Group.

Consequently, the Board of Directors confirms in principle that in application of the Law of 3 July 2008, the AFEP/MEDEF code, as amended, will be the benchmark the Group will refer to in the preparation of the Chairman of the Board's report on corporate governance, which will explain and specify the rules implemented by the Group.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhinoconjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 20% of its sales in gross resources to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitization tablets.

In 2008, Stallergenes had sales of EUR 170.9 million and provided desensitization treatments to more than 500,000 patients.

    Euronext Paris (Compartment B)
    SBF 120.
    ISIN Code: FR0000065674
    Reuters Code: GEN.PA
    Bloomberg Code: GEN.FP

Additional financial information is available at http://www.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
2. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
3. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
4. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
5. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
6. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
7. BIO 2008: Germany on Cutting Edge in Biomanufacturing
8. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
9. Commencement 2008: Student innovation could improve data storage, magnetic sensors
10. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
11. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... SAN DIEGO , Feb. 3, 2016 /PRNewswire/ ... medicine company with the first pluripotent stem cell-derived ... 1 diabetes in clinical-stage development, today announced that ... Janssen Pharmaceutical Companies of Johnson & Johnson, have ... BetaLogics group into ViaCyte.  The agreement provides ViaCyte ...
(Date:2/3/2016)... YORK and HOLLISTON, Mass., Feb. 3, 2016 ... HART ), a biotechnology company developing bioengineered ... trachea and bronchus, today announced that CEO ... BIO CEO & Investor Conference on Tuesday, ... New York City . HART,s ...
(Date:2/3/2016)... ... 03, 2016 , ... StarNet Communications Corp, ( http://www.starnet.com/ ) ... addition of a powerful “Session Preview” feature to its FastX remote Linux visualization ... remote Linux desktop or other applications (sessions) they have running on a remote ...
(Date:2/3/2016)... ... February 03, 2016 , ... ZeptoMetrix™ Corporation (ZMC), ... development and ongoing quality control of molecular assays targeting the Zika Virus. , ... Gregory R. Chiklis, President and CEO of ZeptoMetrix, relayed to his Executive Team. ...
Breaking Biology Technology:
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... 2, 2016   Parabon NanoLabs (Parabon) ... Army Research Office and the Defense Forensics and ... of the company,s Snapshot Kinship Inference ... more generally, defense-related DNA forensics.  Although Snapshot is ... appearance and ancestry from DNA evidence), it also ...
(Date:1/28/2016)... Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), a ... its second quarter ended December 31, 2015. ... of fiscal 2016 increased 2 percent compared to the comparable quarter ... of fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... income for the first quarter of fiscal 2016 grew 9 percent ...
Breaking Biology News(10 mins):